| 05/20 | Merck's Keytruda Receives Positive EMA Panel Opinion as Adjuvant Therapy in Skin Cancer | MT |
| 05/20 | Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treat.. | BU |
| 05/20 | Merck Gets CHMP Backing for Expanded Keytruda Use in Melanoma | DJ |
| 05/17 | Calliditas Therapeutics Starts Enrollment of Mid-Stage Head and Neck Cancer Study | MT |
| 05/17 | Berenberg Bank Adjusts Merck's Price Target to $95 From $87, Maintains Hold Rating | MT |
| 05/16 | Neoleukin Therapeutics Treats First Tumor Patient in Trial Evaluating NL-201 With Keytr.. | MT |
| 05/16 | Athenex, Merck Collaborate to Study Oraxol Plus Keytruda in Non-Small Cell Lung Cancer | MT |
| 05/16 | Athenex, Inc. Announces Clinical Collaboration with Merck to Evaluate Oraxol Plus KEYTR.. | CI |
| 05/16 | Rising Cyber Attacks Could Make Insurance Unaffordable | AQ |
| 05/13 | Tesla, Occidental rise; New Relic, Merck fall | AQ |
| 05/12 | Thinking about trading options or stock in Hess, Electronic Arts, Merck, Microsoft, or .. | PR |
| 05/11 | TRANSCRIPT : Merck & Co., Inc. Presents at Bank of America 2022 Healthcare Conference, May.. | CI |
| 05/10 | SECTOR UPDATE : Health Care Stocks Still Edging Higher This Afternoon | MT |
| 05/10 | Merck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medic.. | BU |
| 05/10 | Merck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medic.. | CI |
| 05/05 | MERCK & CO., INC. Management's Discussion and Analysis of Financial Condition and Resu.. | AQ |
| 05/05 | Nabriva Therapeutics Signs Extended Deal With Merck to Promote, Distribute Sivextro Thr.. | MT |
| 05/05 | Nabriva Extends Exclusive Agreement to Promote and Distribute Sivextro® (Tedizolid Phos.. | CI |
| 05/04 | Amphista Therapeutics Announces Strategic Collaboration with Merck Healthcare, Division.. | CI |
| 05/04 | Merck to Participate in Bank of America Securities 2022 Healthcare Conference | BU |
| 05/02 | Merck - European Commission Approves Merck's KEYTRUDA (pembrolizumab) Plus Chemotherapy.. | AQ |
| 05/02 | Merck - European Commission Approves Merck's KEYTRUDA (pembrolizumab) for Patients With.. | AQ |
| 05/02 | Thinking about trading options or stock in Merck, Tesla, Netflix, Advanced Micro Device.. | PR |
| 05/02 | UNIVERSITY OF CHICAGO : A new technique to delete single atoms can speed up molecule desig.. | AQ |
| 05/01 | Imugene Limited Announces Termination of Supply Agreement | CI |
| 04/29 | Morgan Stanley Adjusts Merck & Co.'s Price Target to $87 from $80, Keeps Equalweight Ra.. | MT |
| 04/29 | Goldman Sachs Adjusts Price Target for Merck & Company to $105 From $101, Maintains Buy.. | MT |
| 04/29 | JPMorgan Adjusts Price Target for Merck & Company to $100 From $95, Maintains Overweigh.. | MT |
| 04/29 | Wells Fargo Raises Merck & Company's Price Target to $105 From $90, Reiterates Overweig.. | MT |
| 04/29 | SVB Leerink Adjusts Merck & Co.'s Price Target to $102 from $97, Keeps Outperform Ratin.. | MT |
| 04/29 | Merck & Co. Receives EU Approval for Cancer Immunotherapy Keytruda | MT |
| 04/29 | Merck Says EC Approves Keytruda Regimen to Treat Advanced Cervical Cancer | MT |
| 04/29 | Ionova Life Science Co., Ltd. Announces Clinical Trial Collaboration with Merck & Co., .. | CI |
| 04/29 | European Commission Approves Merck's KEYTRUDA® (pembrolizumab) for Patients With Micros.. | BU |
| 04/29 | European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With .. | BU |
| 04/29 | Merck Gets Expanded Europe OK for Keytruda in Cervical Cancer | DJ |
| 04/29 | AstraZeneca Moves to Secure Long-Term Growth With New R&D Hub Amid Expected Drop in COV.. | MT |
| 04/28 | COVID-19 treatment, Keytruda boost drugmaker Merck in Q1 | AQ |
| 04/28 | Merck & Co. Lifts 2022 EPS, Sales Guidance | MT |
| 04/28 | MERCK : 1Q22 Merck Earnings Presentation | PU |
| 04/28 | TRANSCRIPT : Merck & Co., Inc., Q1 2022 Earnings Call, Apr 28, 2022 | CI |
| 04/28 | MERCK : Announces First-Quarter 2022 Financial Results - Form 8-K | PU |
| 04/28 | Merck Posts Higher Q1 Adjusted Earnings, Sales; Raises Full-Year 2022 Outlook | MT |
| 04/28 | MERCK : Q1 Earnings Snapshot | AQ |
| 04/28 | GUIDANCE : (MRK) MERCK & CO. Sees Fiscal Year 2022 EPS Range $7.24 - $7.36 | MT |
| 04/28 | GUIDANCE : (MRK) MERCK & CO. Expects Fiscal Year 2022 Revenue Range $56.9B - $58.1B | MT |
| 04/28 | Earnings Flash (MRK) MERCK & CO. Reports Q1 Revenue $15.9B | MT |
| 04/28 | Earnings Flash (MRK) MERCK & CO. Reports Q1 EPS $2.14 | MT |
| 04/28 | Merck Announces First-Quarter 2022 Financial Results | BU |
| 04/28 | Merck & Co., Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 04/28 | Merck & Co., Inc. Provides Earnings Guidance for the Year 2022 | CI |
| 04/26 | Merck Receives Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) Plus Chemotherapy .. | AQ |
| 04/25 | Merck Receives EU Recommendation For Triple-negative Breast Cancer Treatment Approval | MT |
| 04/25 | Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy.. | BU |
| 04/25 | Merck Receives Positive EU Chmp Opinion for Keytruda(R) (Pembrolizumab) Plus Chemothera.. | CI |
| 04/25 | Merck Gets CHMP Backing for Expanded Keytruda Use in Breast Cancer | DJ |
| 04/22 | Pfizer Wins WHO Endorsement For Antiviral Pill In High-Risk COVID-19 Patients | MT |
| 04/21 | PLEADING AND PREEMPTION : Immunization Against Vaccine Products Liability Claims | AQ |
| 04/21 | SVB Leerink Adjusts Merck & Co.'s Price Target to $97 From $100, Keeps Outperform Ratin.. | MT |
| 04/21 | MERCK : Asset Acquisition - Form 8-K | PU |
| 04/21 | MERCK & CO., INC. : Results of Operations and Financial Condition, Other Events, Financial.. | AQ |
| 04/20 | Merck Announces That Joseph Romanelli Will Lead Merck Human Health International, Effec.. | BU |
| 04/18 | Health Canada Approves KEYTRUDA® (pembrolizumab) for the treatment of adult patients wi.. | AQ |
| 04/18 | Merck Receives Approval from Health Canada for KEYTRUDA | CI |
| 04/14 | Merck Receives FDA Breakthrough Therapy Designation for Pneumococcal Conjugate Vaccine | MT |
| 04/14 | Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Com.. | BU |
| 04/14 | Merck Gets FDA Breakthrough Therapy Designation for V116 Vaccine | DJ |
| 04/12 | Barclays Adjusts Price Target for Merck & Company to $97 From $94, Maintains Overweight.. | MT |
| 04/12 | Goldman Sachs Adjusts Price Target for Merck & Company to $101 From $93, Maintains Buy .. | MT |
| 04/11 | Merck Says Health Canada Expands HPV Vaccine Gardasil 9's Marketing Authorization | MT |
| 04/11 | Health Canada Approves GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) .. | AQ |
| 04/11 | Health Canada Approves Merck & Co., Inc.'s Gardasil®9 for the Prevention of Oropharynge.. | CI |
| 04/11 | Merck Gets Approval to Expand Gardasil Indication in Canada | DJ |
| 04/08 | Merck to Hold First-Quarter 2022 Sales and Earnings Conference Call April 28 | BU |
| 04/06 | Morgan Stanley Adjusts Merck & Co.'s Price Target to $80 from $82, Keeps Equalweight Ra.. | MT |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
